Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2012-01-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-11-0820PMID 22248472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Oncogene].

  2019cited by this paper
• Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

  2011influential reference
• An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

  2010cited by this paper
• Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010cited by this paper
• Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

  2010cited by this paper
• HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

  2010cited by this paper
• Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

  2009cited by this paper
• Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

  2009cited by this paper
• Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

  2009cited by this paper
• Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

  2009cited by this paper
• Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

  2009cited by this paper
• Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

  2009cited by this paper
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

  2008cited by this paper
• Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients

  2008cited by this paper
• Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro

  2008cited by this paper
• ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.

  2008cited by this paper
• Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

  2008cited by this paper
• Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

  2007cited by this paper
• Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin*

  2007cited by this paper
• Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

  2007cited by this paper
• Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3

  2007cited by this paper
• Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways

  2006cited by this paper
• The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors

  2006cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006influential reference
• Isolation of scFvs to In Vitro Produced Extracellular Domains of EGFR Family Members

  2005cited by this paper
• Engineered antibody fragments and the rise of single domains

  2005cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells

  2003cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper
• The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan

  2003cited by this paper
• The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

  2003cited by this paper
• The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

  2002cited by this paper
• Development of stable cell lines for production or regulated expression using matrix attachment regions.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

  2001cited by this paper
• Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy.

  1999cited by this paper
• Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4

  1998cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.

  1996cited by this paper
• In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.

  1995cited by this paper

• The making of multispecific immunoglobulins – a clinical perspective

  2026cites this paper
• Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials.

  2025cites this paper
• Type I RTKs: ErbB (epidermal growth factor) receptor family in GtoPdb v.2025.3

  2025cites this paper
• DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer

  2025cites this paper
• Anticancer drug synergy prediction based on CatBoost

  2025cites this paper
• Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

  2024cites this paper
• A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion

  2024cites this paper
• Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: Preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications

  2024influential citation
• The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer

  2024cites this paper
• HER3: Updates and current biology function, targeted therapy and pathologic detecting methods.

  2024cites this paper
• Therapeutic potential of cis-targeting bispecific antibodies.

  2024cites this paper
• Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo

  2024cites this paper
• HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs

  2024cites this paper
• Design and engineering of bispecific antibodies: insights and practical considerations

  2024cites this paper
• Emerging Targeted Therapies for HER2-Positive Breast Cancer

  2023cites this paper
• Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

  2023cites this paper
• Addressing the in vivo delivery of nucleic-acid nanostructure therapeutics.

  2023cites this paper
• Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a ‐f

  2023cites this paper
• Targeting HER2 and FGFR-positive cancer cells with a bispecific cytotoxic conjugate combining anti-HER2 Affibody and FGF2.

  2023cites this paper
• Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats

  2023cites this paper
• Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma

  2023cites this paper
• Recent advancements in fusion protein technologies in oncotherapy: A review.

  2023cites this paper
• Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

  2023influential citation
• HER3-targeted therapeutic antibodies and antibody–drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors

  2023cites this paper
• Novel HER-2 Targeted Therapies in Breast Cancer

  2023cites this paper
• Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling

  2022cites this paper
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition

  2022cites this paper
• Emerging new therapeutic antibody derivatives for cancer treatment

  2022cites this paper
• HER3 in cancer: from the bench to the bedside

  2022cites this paper
• Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers

  2022cites this paper
• MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

  2022cites this paper
• Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation.

  2022cites this paper
• Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions

  2022cites this paper
• From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

  2022cites this paper
• Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

  2022cites this paper
• Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

  2022cites this paper
• Immunotherapy and immunobiomarker in breast cancer: current practice and future perspectives.

  2022cites this paper
• Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma

  2022cites this paper
• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• Recent advances and challenges of bispecific antibodies in solid tumors

  2021cites this paper
• The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.

  2021cites this paper
• HER3 PET Imaging Identifies Dynamic Changes in HER3 in Response to HER2 Inhibition with Lapatinib

  2021cites this paper
• A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

  2021cites this paper
• Epithelial-specific ERBB3 deletion results in a genetic background-dependent increase in intestinal and colon polyps that is mediated by EGFR

  2021cites this paper
• Serum albumin: clinical significance of drug binding and development as drug delivery vehicle.

  2021cites this paper
• Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

  2021cites this paper
• A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

  2021cites this paper
• HER 3 PET Imaging Identi � es HER 2 + Breast Cancers That Bene � t From HER 3 Inhibitor Addition

  2021cites this paper
• Bispecific antibodies for the treatment of breast cancer

  2021cites this paper
• The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy.

  2021cites this paper
• A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo

  2021cites this paper
• Pseudokinases: Prospects for expanding the therapeutic targets armamentarium.

  2021cites this paper
• The renaissance of chemically generated bispecific antibodies

  2021cites this paper
• Chemically Generated Bispecific Antibodies – A New Dawn

  2021cites this paper
• Rational nanocarrier design towards clinical translation of cancer nanotherapy

  2021cites this paper
• The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers

  2021cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Advances of the Application of Liposomal Nanosystems in Anticancer Therapy.

  2020cites this paper
• The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo

  2020cites this paper
• [Recent advances in the development of bispecific antibodies].

  2020cites this paper
• Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids

  2020cites this paper
• Development of bispecific antibodies in China: overview and prospects

  2020cites this paper
• Selected updates in molecular and genomic pathology of esophageal cancer

  2020cites this paper
• HER3 PET Imaging Identifies HER2+ Breast Cancers That Benefit From HER3 Inhibitor Addition  

  2020cites this paper
• Albumin: An Emerging Opportunity in Drug Delivery

  2020cites this paper
• Live long and active: Polypeptide-mediated assembly of antibody variable fragments.

  2020cites this paper
• Bispecific antibodies: a novel approach for targeting prominent biomarkers

  2020cites this paper
• Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors

  2020cites this paper
• AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design

  2020influential citation
• Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

  2019cites this paper
• Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies

  2019cites this paper
• Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

  2019cites this paper
• The human epidermal receptors in gastric cancer: molecular alterations and its role as therapeutic targets

  2019cites this paper
• Structural insight into a matured humanized monoclonal antibody HuA21 against HER2-overexpressing cancer cells.

  2019cites this paper
• Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules

  2019cites this paper
• A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

  2019cites this paper
• Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

  2019cites this paper
• Design and Production of Bispecific Antibodies

  2019cites this paper
• Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow

  2019influential citation
• Overexpression of HER2/HER3 and clinical feature of ovarian cancer

  2019cites this paper
• What therapies are on the horizon for HER2 positive breast cancer?

  2019cites this paper
• Special Section on Drug Delivery Technologies — Minireview Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics

  2019cites this paper
• Novel roles of ErbB3 receptor tyrosine kinase in vesicular trafficking

  2019cites this paper
• HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model

  2019cites this paper
• Targeting the ErbB Family in Head and Neck Cancer

  2018cites this paper
• Current therapeutic landscape for advanced gastroesophageal cancers.

  2018cites this paper
• HER-3 Knocking Down Induces G2/M Arrest in Gastric Cancer Cells

  2018cites this paper
• Multifunctional quantum dots and liposome complexes in drug delivery

  2018cites this paper
• CD59: a promising target for tumor immunotherapy.

  2018cites this paper
• Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.

  2018cites this paper
• Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

  2018cites this paper
• Understanding the biology of HER3 receptor as a therapeutic target in human cancer

  2018cites this paper
• ENGINEERED MULTIVALENCY FOR ENHANCED AFFIBODY-BASED HER3 CANCER THERAPY

  2018influential citation
• The role of ErbB3 binding protein 1 in cancer: Friend or foe?

  2018cites this paper
• Context‐dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches

  2018cites this paper
• Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

  2018cites this paper
• Targeting HER2 by Combination Therapies.

  2018cites this paper
• Targeting the MMP-14/MMP-2/integrin αvβ3 axis with multispecific N-TIMP2–based antagonists for cancer therapy

  2018cites this paper